Stock Research for ADRD

ADRD

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ADRD Stock Chart & Research Data

The ADRD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ADRD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ADRD Due diligence Resources & Stock Charts

The ADRD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ADRD Detailed Price Forecast - CNN Money CNN View ADRD Detailed Summary - Google Finance
Yahoo View ADRD Detailed Summary - Yahoo! Finance Zacks View ADRD Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ADRD Trends & Analysis - Trade-Ideas Barrons View ADRD Major Holders - Barrons
NASDAQ View ADRD Call Transcripts - NASDAQ Seeking View ADRD Breaking News & Analysis - Seeking Alpha
Spotlight View ADRD Annual Report - CompanySpotlight.com OTC Report View ADRD OTC Short Report - OTCShortReport.com
TradeKing View ADRD Fundamentals - TradeKing Charts View ADRD SEC Filings - Bar Chart
WSJ View Historical Prices for ADRD - The WSJ Morningstar View Performance/Total Return for ADRD - Morningstar
MarketWatch View the Analyst Estimates for ADRD - MarketWatch CNBC View the Earnings History for ADRD - CNBC
StockMarketWatch View the ADRD Earnings - StockMarketWatch MacroAxis View ADRD Buy or Sell Recommendations - MacroAxis
Bullish View the ADRD Bullish Patterns - American Bulls Short Pains View ADRD Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ADRD Stock Mentions - StockTwits PennyStocks View ADRD Stock Mentions - PennyStockTweets
Twitter View ADRD Stock Mentions - Twitter Invest Hub View ADRD Investment Forum News - Investor Hub
Yahoo View ADRD Stock Mentions - Yahoo! Message Board Seeking Alpha View ADRD Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for ADRD - SECform4.com Insider Cow View Insider Transactions for ADRD - Insider Cow
CNBC View ADRD Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ADRD - OTC Markets
Yahoo View Insider Transactions for ADRD - Yahoo! Finance NASDAQ View Institutional Holdings for ADRD - NASDAQ


Stock Charts

FinViz View ADRD Stock Insight & Charts - FinViz.com StockCharts View ADRD Investment Charts - StockCharts.com
BarChart View ADRD Stock Overview & Charts - BarChart Trading View View ADRD User Generated Charts - Trading View


Latest Financial News for ADRD

GlaxoSmithKline’s Vaccine Business in 1Q18
Posted on Monday April 30, 2018

GlaxoSmithKline’s (GSK) Vaccine business includes vaccines for meningitis, influenza, and shingles as well as established vaccines. GlaxoSmithKline had acquired meningitis vaccines from Novartis (NVS) in 2016.


Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release
Posted on Wednesday April 25, 2018

In 1Q18, analysts expect Sanofi’s (SNY) revenue to fall ~6.6% YoY (year-over-year) to 8.1 billion euros from 8.7 billion euros, and its earnings per share to fall to 1.13 euros from 1.42 euros. Sanofi’s stock price has fallen ~9.4% over the last 12 months and ~7.1% year-to-date. Analysts’ price target of $47.67 suggests the stock could return ~19.2% over the next 12 months based on its price of $39.95 on April 23.


Novartis’s 1Q18 Estimates: Expectations for Alcon
Posted on Wednesday April 18, 2018

Alcon, Novartis’s (NVS) eye care business, includes surgical products and vision care products. Alcon products are marketed in over 180 countries worldwide. Alcon is expected to report growth in revenue following increased demand for contact lenses and surgical products in 1Q18.


What Analysts Recommend for AstraZeneca in March 2018
Posted on Wednesday March 14, 2018

As discussed earlier, AstraZeneca surpassed Wall Street analyst estimates for earnings per share (or EPS) and revenues and reported EPS of $1.03 on revenues of ~$5.8 billion in 4Q17, a 3% increase in revenues as compared to revenues of 4Q16. AstraZeneca’s stock price has increased by nearly 14.9% over the last 12 months but decreased by ~2.6% in 2018 year-to-date. Wall Street analysts have a 12-month target price of $39.09 per share as compared to the last price of $33.78 per share as of March 8, 2018.


Enter a stock symbol to view the stock details.